摘要
目的对比分析慢性肾脏病合并肾性贫血患者分别采用重组人促红素与罗沙司他治疗的效果及安全性。方法抽选2020年6月-2022年3月本院接诊慢性肾脏病合并肾性贫血患者80例研究,根据随机蓝白小球抽签结果划分对照组(白色小球,40例)与观察组(蓝色小球,40例),对照组患者采用药物重组人促红素治疗,观察组患者采用药物罗沙司他治疗,观察比较治疗效果,检测各组患者治疗前后贫血指标、铁代谢指标,对比差异性,观察统计两组患者治疗一段时间后不良反应情况。结果观察组患者治疗总有效率高于对照组(P<0.05),两组患者治疗前分别检测贫血指标、铁代谢指标,结果比较无统计学差异(P>0.05),治疗后,观察组患者血液指标检测结果均高于对照组(P<0.05),铁代谢指标与对照组相比同样存在统计学差异(P<0.05)。此外,观察组患者治疗后不良反应发生概率低于对照组(P<0.05)。结论临床治疗慢性肾脏病合并肾性贫血可优先选择罗沙司他药物,能够有效改善患者血液指标,调节铁代谢能力,效果理想,同时安全性佳,倡导运用推广。
Objective To compare and analyze effect and safety of recombinant human erythropoietin and rosacetam in treatment of chronic kidney disease with renal anemia.Methods The paper chose 80 patients with chronic kidney disease complicated with renal anemia admitted to our hospital from June 2020 to March 2022,and divided them into control group(40 cases with white balls)and observation group(40 cases with blue balls)according to result of random blue and white ball drawing.Control group was treated with drug recombinant human erythropoietin,while observation group with drug rosacetam.Treatment effect was observed and compared,anemia indicators were measured before and after treatment in each group,difference in iron metabolism indicators was compared,adverse reactions between two groups were observed and analyzed after treatment for a period of time.Results Total effective rate of treatment in observation group was higher than control group(P<0.05).Anemia indicators and iron metabolism indicators were tested before treatment in both groups,there was no statistically significant difference(P>0.05).After treatment,blood indicators of observation group were higher than control group(P<0.05),there was also statistically significant difference(P<0.05).Iron metabolism indicators showed statistically significant difference compared to control group,(P<0.05).In addition,incidence of adverse reactions in observation group after treatment was lower than control group(P<0.05).Conclusion In clinical treatment of chronic kidney disease combined with renal anemia,rosalitam should be treated as priority,it can improve blood indicators,regulate iron metabolism ability of patients effectively,with ideal effect and good safety,which is worthy of application and promotion.
作者
陆静娟
LU Jingjuan(Nephrology Department,Changshu City The Second People's Hospital,Changshu,Jiangsu 215500)
出处
《智慧健康》
2023年第9期237-241,共5页
Smart Healthcare
关键词
罗沙司他
重组人促红素
慢性肾脏病
肾性贫血
铁代谢
Rosastatin
Recombinant human erythropoietin
Chronic kidney disease
Renal anemia
Iron metabolism
作者简介
陆静娟(1985-),女,汉族,江苏常熟,硕士,副主任医师,研究方向:肾内科方面。
